Merging of different risk-adapted approaches. The flowchart shows the hypothetical numbers of patients who would receive escBEACOPP if the RATHL and AHL2011 approaches are merged. The estimated figures are derived from the results of both trials, with extrapolation from the results of RATHL assuming that, after a negative interim PET, AVD is equivalent to ABVD.